AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Temporal Trends of Low Density Lipoprotein Cholesterol Levels and Lipid Lowering Therapy Intensity in a Large Registry of Patients Undergoing Percutaneous Coronary Intervention
By Procopi N, Gitto M, Oliva A et al.
Introduction: Patients with coronary artery disease (CAD) are at high residual cardiovascular risk, requiring intensive lipid-lowering therapy (LLT), including high-intensity statins (HIS), to achieve low-density lipoprotein cholesterol (LDL-C) targets. Research Question: In a large contemporary registry of patients with CAD treated by percutaneous coronary intervention (PCI), what are the temporal trends of LDL-C levels and LLT intensity? Methods: We included consecutive patients with available LDL-C measurement at admission for PCI between January 2012 and December 2023 at a large US tertiary center. Patients with cardiac arrest, cardiogenic shock, active cancer, or dialysis were excluded. Patients were stratified by admission LDL-C levels (<55,55-69,70-99,≥100 mg/dL) and statin intensity (high intensity statin [HIS]: rosuvastatin 20-40 mg or atorvastatin 40-80 mg; low to moderate intensity statin; and no statin). Mean LDL-C levels and LLT distribution are reported annually to assess temporal trends. Logistic regression was performed to estimate the odds ratio (OR) of LLT prescription per one-year increment in time. Results: Among 24,003 patients included (mean age 67±11 years; 29% women), 8,952 (37.3%) were on HIS, 8,222 (34.3%) on low to moderate intensity statin, and 6,829 (28.5%) not on statin at admission. Ezetimibe was prescribed in 1,210 (5.0%) patients. The use of PCSK9 inhibitors (PCSK9i) was at 1.5% between 2018 and 2023. Patients with the highest levels of LDL-C (≥100 mg/dL) compared with those with LDL-C<55 mg/dL were more frequently women (35% vs. 22%) and younger (63.8 vs. 68 years). LLT intensity increased over time for statin use (OR 1.15/year, 95%CI 1.14-1.16), ezetimibe (OR 1.19/year, 95%CI 1.01-1.12), and PCSK9i (OR 1.43/year, 95%CI 1.35-1.52 since 2017) ( Figure 1 ). Despite LLT intensification, more than 50% of patients had LDL-C levels above the target of 70 mg/dL, and mean LDL-C levels remained above this threshold throughout the study period ( Figure 2 ). Overall, 5,468 patients (22.9%) were eligible for PCSK9 inhibitors with a Class I indication according to the 2026 ACC/AHA guidelines. Conclusions: Despite increasing statin intensity over time, mean LDL-C levels remained stable and above 70 mg/dL, supporting greater use of non-statin lipid-lowering therapies, including PCSK9 inhibitors, for which 1 in 5 patients were eligible. Moreover, 30% of patients were not receiving statins at admission, suggesting undervaluation of cardiovascular risk, particularly in women and younger patients.